Mangrove Partners Arcus Biosciences, Inc. Transaction History
Mangrove Partners
- $637 Million
- Q1 2025
A detailed history of Mangrove Partners transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Mangrove Partners holds 83,997 shares of RCUS stock, worth $719,854. This represents 0.1% of its overall portfolio holdings.
Number of Shares
83,997Holding current value
$719,854% of portfolio
0.1%Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
202Shares Held
63.1MCall Options Held
116KPut Options Held
116K-
Black Rock Inc. New York, NY9.76MShares$83.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.69MShares$57.3 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA5.13MShares$43.9 Million0.28% of portfolio
-
State Street Corp Boston, MA3.7MShares$31.7 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.87MShares$24.6 Million0.06% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $618M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...